Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells

Samantha J. Willey
University of Massachusetts Medical School

Jacqueline D. Reeves

Richard Hudson

See next page for additional authors

Follow this and additional works at: http://escholarship.umassmed.edu/oapubs

Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

Repository Citation
Willey, Samantha J.; Reeves, Jacqueline D.; Hudson, Richard; Miyake, Koichi; Dejucq, Nathalie; Schols, Dominique; De Clercq, Erik; Bell, Jeanne E.; McKnight, Aine; and Clapham, Paul R., "Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells" (2003). Open Access Articles. 1529.
http://escholarship.umassmed.edu/oapubs/1529

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells

Authors
Samantha J. Willey, Jacqueline D. Reeves, Richard Hudson, Koichi Miyake, Nathalie Dejucq, Dominique Schols, Erik De Clercq, Jeanne E. Bell, Aine McKnight, and Paul R. Clapham

Rights and Permissions
Citation: J Virol. 2003 Jun;77(11):6138-52.

This article is available at eScholarship@UMMS: http://escholarship.umassmed.edu/oapubs/1529
Identification of a Subset of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus Strains Able To Exploit an Alternative Coreceptor on Untransformed Human Brain and Lymphoid Cells

Samantha J. Willey,1,2 Jacqueline D. Reeves,3 Richard Hudson,1 Koichi Miyake,4 Nathalie Dejucq,5 Dominique Schols,6 Erik De Clercq,6 Jeanne Bell,7 Aine McKnight,2 and Paul R. Clapham1*

Center for AIDS Research, Program in Molecular Medicine, Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester, Massachusetts 01605; Wohl Virion Centre, Department of Immunology and Molecular Pathology, Windeyer Institute of Medical Sciences, London WIT 4JF; and Department of Neuropathology, University of Edinburgh, Edinburgh, United Kingdom; Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104; Department of Biochemistry and Molecular Biology, Nippon Medical School, Bunkyo-ku, Tokyo 113-8602, Japan; GERM-INSERM U435, 35 042 Rennes Cedex, France; and Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 EH4 2XU, Leuven, Belgium

Received 3 December 2002/Accepted 4 March 2003

The chemokine receptors CCR5 and CXCR4 are the major coreceptors for human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV). At least 12 other chemokine receptors or close relatives support infection by particular HIV and SIV strains on CD4+ transformed indicator cell lines in vitro. However, the role of these alternative coreceptors in vivo is presently thought to be insignificant. Infection of cell lines expressing high levels of recombinant CD4 and coreceptors thus does not provide a true indication of coreceptor use in vivo. We therefore tested primary untransformed cell cultures that lack CCR5 and CXCR4, including astrocytes and brain microvascular endothelial cells (BMVECs), for naturally expressed alternative coreceptors functional for HIV and SIV infection. An adenovirus vector (Ad-CD4) was used to express CD4 and cellular membranes and releasing the viral core into the cytoplasm. Fusion is initiated upon interaction of the trimeric viral envelope glycoprotein and the primary host cell receptor CD4 (21, 42). A conformational change in gp120 structure reveals a coreceptor-binding site, and the subsequent interaction with a coreceptor instigates further structural changes in gp41 and membrane fusion. The seven-transmembrane G-protein-coupled chemokine receptors CCR5 and CXCR4 are the major coreceptors used for HIV and SIV infection in vivo (2, 24, 30). Cell tropism of HIV and SIV strains is largely determined by the expression of CD4 and these coreceptors. Cell tropism plays a role in both virus transmission and disease progression (39). The majority of transmitted viruses are R5- or M-tropic, highlighted by the substantial protection from infection observed in individuals homozygous for a 32-bp deletion in CCR5 (23, 47, 58). CCR5-using variants emerge late in disease in up to 50% of AIDS patients (72). This change in coreceptor use correlates with disease progression in infected individuals (19, 60), although it is not a prerequisite, as not all infected individuals demonstrate a coreceptor switch (26). Although primary X4 strains can infect macrophages via CXCR4 (67, 75, 77), these variants primarily target new populations of T cells that express CXCR4 but not CCR5, e.g., naive T-cells (7, 52).

Although CCR5 and CXCR4 are the major coreceptors used in vivo, there are at least 12 other members of the chemokine receptor family, and related “orphan” receptors, that can support infection of indicator cell lines in vitro (5, 16, 27, 55). These include CCR3 (14, 28), CCR8 (55), GPR1 (34, 63), GPR15 (34), CXCR6 (3, 25), Apj (13, 31), and RDC1 (64). In general, HIV type 2 (HIV-2) and SIV strains use a wider range of these alternative coreceptors than HIV-1, frequently as efficiently as they use CCR5 and/or CXCR4 (16, 53). For HIV-1,

Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infect cells by inducing fusion of viral and cellular membranes and releasing the viral core into the cytoplasm. Fusion is initiated upon interaction of the trimeric viral envelope glycoprotein and the primary host cell receptor CD4 (21, 42). A conformational change in gp120 structure reveals a coreceptor-binding site, and the subsequent interaction with a coreceptor instigates further structural changes in gp41 and membrane fusion. The seven-transmembrane G-protein-coupled chemokine receptors CCR5 and CXCR4 are the major coreceptors used for HIV and SIV infection in vivo (2, 24, 30). Cell tropism of HIV and SIV strains is largely determined by the expression of CD4 and these coreceptors. Cell tropism plays a role in both virus transmission and disease progression (39). The majority of transmitted viruses are R5- or M-tropic, highlighted by the substantial protection from infection observed in individuals homozygous for a 32-bp deletion in CCR5 (23, 47, 58). CCR5-using variants emerge late in disease in up to 50% of AIDS patients (72). This change in coreceptor use correlates with disease progression in infected individuals (19, 60), although it is not a prerequisite, as not all infected individuals demonstrate a coreceptor switch (26). Although primary X4 strains can infect macrophages via CXCR4 (67, 75, 77), these variants primarily target new populations of T cells that express CXCR4 but not CCR5, e.g., naive T-cells (7, 52).

Although CCR5 and CXCR4 are the major coreceptors used in vivo, there are at least 12 other members of the chemokine receptor family, and related “orphan” receptors, that can support infection of indicator cell lines in vitro (5, 16, 27, 55). These include CCR3 (14, 28), CCR8 (55), GPR1 (34, 63), GPR15 (34), CXCR6 (3, 25), Apj (13, 31), and RDC1 (64). In general, HIV type 2 (HIV-2) and SIV strains use a wider range of these alternative coreceptors than HIV-1, frequently as efficiently as they use CCR5 and/or CXCR4 (16, 53). For HIV-1,
there is little current evidence to indicate that alternative coreceptors (other than CCR5 and CXCR4) contribute to viral replication in vivo (79). The ability of HIV-1 strains to exploit alternative coreceptors on the surfaces of cell lines therefore does not provide a true indication of coreceptor usage properties in vivo. The capacity of naturally expressed coreceptors (other than CCR5 and CXCR4) to support HIV infection of primary cell cultures may provide a stronger indication for their use in vivo. Thus, it has been reported that a maternal isolate used CXCR6 in addition to CCR5 and CXCR4 on indicator cell lines and replicated in CCR5− peripheral blood mononuclear cells (PBMCs) in the presence of a CXCR4 inhibitor (61, 79). Similarly, Lee et al. reported that CCR8 supported infection of primary thymocytes by particular HIV-1 isolates (45).

In this study, we have investigated whether functional coreceptors can be detected on different primary or untransformed human cell cultures. We report the identification of a subset of HIV and SIV strains that are able to exploit an unknown coreceptor naturally expressed on brain microvascular endothelial cells (BMVECs) and astrocyte cultures. Moreover several of these HIV-1 and HIV-2 strains were able to replicate in CCR5− PBMCs with CXCR4 blocked by the bicyclam AMD3100. Replication of such strains was inhibited by the chemokine vMIP-I, implicating an unknown vMIP-I receptor as the coreceptor involved.

**MATERIALS AND METHODS**

**Viruses.** SF162 is a non-syncytium-inducing molecular clone of HIV-1 which uses primarily CCR5 as a coreceptor (12). The HIV-1 isolate 2044 utilizes CXCR4 as a coreceptor and has been previously described (68). GUN-1v is a variant of the T-cell-line-adapted HIV-1 isolate GUN-1WT, which was isolated by its ability to infect brain-derived BT cells derived from human meningioma tissue (71). The HIV-1 strain 89.6 is an R5X4 molecular clone of HIV-1 (18), as is the isolate HAN-2 (59). The R5X4 HIV-1 isolate P1019 is a pediatric strain isolated from a 3-year-old child (36). All isolates of HIV-1 used in this study are clade B. The HIV-2 isolates used here are all Portuguese primary isolates from individuals of West African descent (50, 54). ALI was derived from a patient with AIDS-related complex. TER, JAU, MIL, and SAB were isolated from AIDS patients, and the R5X4 isolates JAU, MLC, and ETP originated from symptom-atatic patients (54). The HIV-1 strain SIVmac239, containing the env and nef genes and the entire 3’ long terminal repeat from the neurovirulent SIVmac239 clone SIV/17E-Br (35). SIVman4 is a T-cell-line-adapted variant of SIVsmB670 (51). The coreceptor use of most of the virus isolates used in this study has been previously described (46, 54) and is summarized in Table 1. All virus stocks were propagated in PBMCs purified from whole blood by density gradient centrifugation and stimulated for 2 days in phytohemagglutinin (1 μg/ml) (Sigma) and for 2 days in human recombinant IL-2 (20 U/ml) (Roche, Inc.), with the exception of GUN-1v, which was passaged in the T-cell line MOLT4 clone 8. The replication-defective adenovirus vector carrying the human CD4 gene (Ad-CD4) (76) was propagated in the cell line 293.

When cytopathicity was observed, cells were pelleted by centrifugation, the supernatant was discarded, and the cells were suspended in fresh Dulbecco’s modified Eagle’s medium (DMEM) (Gibco Invitrogen Corporation) with 10% fetal bovine serum (FBS). Cells were lysed by freeze-thawing three times to release intracellular virus, and cell debris was removed by centrifugation. Ad-CD4 was titrated on NP2/CCR5 cells (see below) and subsequently challenged with serially diluted SF162. The Ad-CD4 dilution that conferred maximum release intracellular virus, and cell debris was removed by centrifugation. Ad-CD4 was titrated on NP2/CCR5 cells (see below) and subsequently challenged with serially diluted SF162. The Ad-CD4 dilution that conferred maximum

<table>
<thead>
<tr>
<th>VIRUS</th>
<th>CCR5</th>
<th>CXCR4</th>
<th>CCR3</th>
<th>CCRI</th>
<th>GPR1</th>
<th>Apj</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF162</td>
<td>7.2 × 10^5</td>
<td>0</td>
<td>8.8 × 10^3</td>
<td>2.1 × 10^2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2044</td>
<td>0</td>
<td>1.0 × 10^5</td>
<td>0</td>
<td>1.0 × 10^2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>89.6</td>
<td>3.0 × 10^5</td>
<td>5.0 × 10^5</td>
<td>8.0 × 10^3</td>
<td>2.6 × 10^2</td>
<td>0</td>
<td>1.3 × 10^4</td>
</tr>
<tr>
<td>GUN-1v</td>
<td>2.2 × 10^5</td>
<td>5.5 × 10^5</td>
<td>8.0 × 10^2</td>
<td>2.5 × 10^2</td>
<td>3.0 × 10^2</td>
<td>0</td>
</tr>
<tr>
<td>HAN-2</td>
<td>1.0 × 10^5</td>
<td>2.4 × 10^5</td>
<td>1.5 × 10^3</td>
<td>3.6 × 10^2</td>
<td>2.0 × 10^2</td>
<td>0</td>
</tr>
<tr>
<td>P1019</td>
<td>2.2 × 10^5</td>
<td>2.0 × 10^5</td>
<td>1.7 × 10^3</td>
<td>1.7 × 10^3</td>
<td>4.8 × 10^2</td>
<td>0</td>
</tr>
<tr>
<td>HIV-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TER</td>
<td>2.3 × 10^5</td>
<td>0</td>
<td>1.6 × 10^3</td>
<td>4.6 × 10^2</td>
<td>6.7 × 10^2</td>
<td>0</td>
</tr>
<tr>
<td>ETP</td>
<td>1.7 × 10^5</td>
<td>2.5 × 10^4</td>
<td>0</td>
<td>8.0 × 10^4</td>
<td>0</td>
<td>2.3 × 10^3</td>
</tr>
<tr>
<td>JAU</td>
<td>4.5 × 10^5</td>
<td>4.7 × 10^2</td>
<td>1.3 × 10^3</td>
<td>2.7 × 10^3</td>
<td>1.7 × 10^3</td>
<td>2.5 × 10^2</td>
</tr>
<tr>
<td>ALI</td>
<td>8.0 × 10^5</td>
<td>1.0 × 10^3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NTb</td>
</tr>
<tr>
<td>SAB</td>
<td>0</td>
<td>1.0 × 10^5</td>
<td>8.0 × 10^4</td>
<td>0</td>
<td>0</td>
<td>NT</td>
</tr>
<tr>
<td>SIV (Man4)</td>
<td>2.1 × 10^4</td>
<td>1.4 × 10^3</td>
<td>1.3 × 10^3</td>
<td>0</td>
<td>3.0 × 10^2</td>
<td>1.5 × 10^2</td>
</tr>
</tbody>
</table>

* NT, not tested.

**a** Coreceptor use by HIV and SIV isolates that use an alternative coreceptor on BMVEC and astrocyte cultures was determined by titration on the cell line N P2 (for all of the HIV-1 isolates, HIV-2 TER, ETP, and JAU, and SIVman4), U87 (for HIV-2 ALI and HIV-2 SAB with all coreceptors except CCR3), or GHOST (for HIV-2 SAB with CCR3), stably expressing CD4 and a range of coreceptors. Cells were incubated with 100 μl of 10-fold dilutions of virus stock for 3 h before being washed and incubated at 37°C for 72 h. Infected cells were detected by immunostaining for intracellular p24. The data as presented represent results compiled from several experiments.
tissue was resuspended in DMEM and passed through a cell strainer until all cell clumps were removed. The cell suspension was centrifuged for 5 min at 210 × g before the pellet was resuspended in DMEM–10% FBS and seeded into T25 tissue culture flanks. After cells had adhered, astrocytes were purified by mixed brain culture by agitation on a plate shaker at 37°C for 1 to 2 h. Cells were washed in serum-free medium before incubation for 1 to 2 days in DMEM–10% FBS and reshaking as described above. Following a further 2-day incubation, the purity of astrocytes was determined by staining for the astrocytic marker glial fibrillary acidic protein as described below. Astrocyte cultures were maintained in DMEM with gentamicin and 10% FBS. Fetal astrocytes showed high plating efficiency, with about 100× recovery from dispersed temporal lobectomy samples was massively reduced.

**Inhibitors and antibodies.** The chemokine RANTES was purchased from PeproTech Inc., Rocky Hill, N.J. The N-terminally modified RANTES analogue AOP-RANTES was provided by Amanda Proudfoot, Serono Inc, Geneva, Switzerland. The chemokines I59 and eotaxin and the human herpesvirus 8 (HHV8)-encoded chemokines vMIP-I and vMIP-II were purchased from R&D Systems, Inc. The CXCR4 antagonist AMD3100 was provided by AnorMED Inc., Langley, Canada. The small-molecule inhibitor TAK-779 was obtained through the AIDS Research and Reference Reagent Program from James Hoxie (32). The CD4 coreceptor in the observed low-level infection is unclear (8, 56). In order to determine if the cultured fetal and adult astrocytes do not usually express CD4 and therefore support only inefficient infection by R5 viruses to levels comparable to those seen with NP2 cells stably expressing both CD4 and CCR5. Astrocytes do not usually express CD4 and therefore support only an inefficient infection by R5 viruses to levels comparable to those seen with NP2 cells stably expressing both CD4 and CCR5. As seen in Fig. 2A, infection of the cell line NP2/CCR5 with Ad-CD4 is sufficient to confer infection by R5 viruses to levels comparable to those seen with NP2 cells stably expressing both CD4 and CCR5. By the same principle, infection of astrocyte cultures with Ad-CD4 enables the screening of a range of HIV and SIV isolates for their capacity to use functional coreceptors expressed on astrocytes that lack CCR5 (fetal) or both CCR5 and CXCR4 (adult). Adult astrocyte cultures (901A and
preinfected with Ad-CD4 were resistant to HIV-1 strains that predominantly used CCR5 (SF162) or CXCR4 (2044). In contrast, three R5X4 HIV-1 strains (P1019, HAN-2, and GUN-1v) and several HIV-2 and SIV strains (TER, ETP, SIVman4, and SIVmac17Efr) were able to infect adult astrocytes (001A and, to various extents, 004.2 (Fig. 2B and C). The fetal astrocyte culture F01 weakly expressed CXCR4 (Fig. 1), and adenovirus-mediated expression of CD4 conferred sensitivity to all isolates that use CXCR4, including the HIV-1 X4 isolate 2044 (Fig. 2D). However, it is likely that the HIV-2 strain TER and SIVman4 exploit an alternative coreceptor for infection of fetal astrocytes, since TER does not use CXCR4 on standard CD4/H11001 indicator cell lines (54), and CXCR4 use by SIVman4 is inefficient and at least 1,000 times less than CCR5 use (data not shown).

Infection of fetal and adult astrocytes is reduced by chemokine receptor ligands. In order to identify the possible coreceptor(s) being exploited for infection, we tested a range of chemokine receptor ligands for their capacity to block infection by HIV-1 GUN-1v. A common feature of the HIV and SIV strains that infected astrocytes was their capacity to exploit CCR3, CCR8, and GPR1 as coreceptors on indicator cell lines (in addition to CCR5 and sometimes CXCR4). We therefore included ligands that bind these chemokine receptors in the inhibition assays. The activities of all coreceptor-specific chemokines and antibodies were determined by carrying out control inhibitions on appropriate coreceptor-expressing cell lines. CCR3- and CCR8-mediated HIV infection was selectively inhibited by the ligands eotaxin and I309, respectively (data not shown). In comparison, vMIP-I (an HHV8-encoded chemokine) inhibited infection of control cell lines expressing CCR8, GPR1, and CXCR6, as previously reported (66), and weakly blocked CCR3-mediated infection (data not shown). GUN-1v infection of adult astrocytes 001A pretreated with Ad-CD4 was reduced to approximately 50% of the levels seen in the absence of inhibitors by both vMIP-I (which binds CCR8, GPR1, and CXCR6) and RANTES (which binds CCR5, CCR1, CCR3, and CCR9). The ligand eotaxin (CCR3, D6) also reduced infectivity to approximately 60%. (Fig. 4A). TAK-779, the CCR5 small-molecule inhibitor, had no effect on 001A infection despite inhibiting GUN-1v infection of CCR5-expressing indicator cell lines by 100% (data not shown). In addition, the CCR5-specific MAb 2D7 failed to block astrocyte infection of coreceptor indicator cell lines in the absence of CD4 was negative (data not shown).

**Infection of fetal and adult astrocytes by HIV-1, HIV-2, and SIV strains in the absence of CD4 expression.** Low-level CD4-independent infection of brain cultures has been reported for various HIV and SIV strains (15, 56). Therefore, we also tested whether fetal and adult astrocytes supported infection by the same panel of HIV and SIV isolates in the absence of adenovirus-mediated CD4 expression. These cultures were negative for CD4 expression by immunohistochemical methods, and infection by most strains was weak, as expected (Fig. 3). The HIV-1 strains SF162 (R5) and 2044 (X4) did not infect either the adult or fetal astrocytes. The R5X4 isolates Han-2 and P1019, as well as the HIV-2 strain TER and the SIV isolates Man4 and 17Efr, gave variable but low infectivity titers on all three astrocyte cultures. The HIV-1 isolate GUN-1v was able to infect both adult astrocyte cultures 004.2 and 001A, even though infection of coreceptor indicator cell lines in the absence of CD4 was negative (data not shown).

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence (5′→3′)</th>
<th>Product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>TGGATATTGCCCATCAATGACC GATGGCATGGACTTGTTGTCATG</td>
<td>457</td>
</tr>
<tr>
<td>CD4</td>
<td>TCAAGGGAAAGAAGTGAGTC AAGAAGGGACGTGATTATTCCC</td>
<td>170</td>
</tr>
<tr>
<td>CCR5</td>
<td>CTCATTACACCTGCGACCTC CACAGCCCTGTTGCTCTTCTTGT</td>
<td>182 (wild type), 150 (Δ32)</td>
</tr>
<tr>
<td>CXCR4</td>
<td>TAGATATCTTACCATGGAGGGGATCAG TAGCGGCGCTTAGGGAGAAACTTG</td>
<td>1,044</td>
</tr>
<tr>
<td>CCR8</td>
<td>GCAAGTGTGCTCTTCGTGCTC ATGGGTTGCGATAGTACCG</td>
<td>710</td>
</tr>
<tr>
<td>CCR3</td>
<td>GCTGATACACAGACCTGATG CAACAAAGGCGCAGACCCG</td>
<td>834</td>
</tr>
<tr>
<td>GPR1</td>
<td>CCAGCTGGGAGTTGTGTTGTTACT GCTGTTTCCAGGAGACACAG</td>
<td>1,068</td>
</tr>
<tr>
<td>GPR15</td>
<td>ATGGACCCAGAAGAAACTTC TTAGATGCGAAGACACCC</td>
<td>1,100</td>
</tr>
<tr>
<td>CXCR6</td>
<td>CAGGCATCCATGAATGGGTGT CAAGCTATAAAGTGGAAACATGCTG</td>
<td>766</td>
</tr>
<tr>
<td>RDC1</td>
<td>AGAGAAGATGTGGTACGGCCTGCTGTGCTGCATCTTG CTCGCTGTGCTTCTCTGGTGACTGGACGCGAG</td>
<td>280</td>
</tr>
</tbody>
</table>

---

**TABLE 2. Oligonucleotide sequences used for the amplification of HIV and SIV receptors and coreceptors**
FIG. 1. Immunostaining of astrocyte cultures. All astrocyte cultures and control cells were seeded onto 13-mm-diameter glass coverslips the day before being stained for CD4 (Q4120), CCR5 (2D7), CXCR4 (12G5), and GFAP, a marker for astrocytes. Nuclei of antigen-negative cells were stained with propidium iodide (red).
FIG. 2. CD4 expression on astrocytes confers susceptibility to infection with HIV and SIV. (A) The activity of Ad-CD4 was tested by pretreating NP2/CCR5 cells with Ad-CD4 for 3 h, rinsing, and incubating overnight. Ad-CD4-pretreated and untreated NP2/CCR5 cells, as well as NP2 cells stably expressing CD4 and CCR5, were exposed to the R5-using HIV-1 strain SF162 for 3 h, and infected cells detected by p24 immunostaining were counted after 72 h. (B) Untransformed GFAP-positive adult astrocytes 001A and 004.2 were pretreated with Ad-CD4 before infection with the HIV-1, HIV-2, and SIV strains shown. After 72 h, cells were fixed and stained for intracellular viral antigens. (C and D) The titer of each HIV or SIV isolate was assessed on adult astrocytes 001A and 004.2 (C) and fetal astrocytes F01 (D). Cells were exposed to Ad-CD4 and infected as described above. All HIV and SIV isolates tested had titers of between $1 \times 10^5$ and $5 \times 10^5$ FFU/ml on NP2/CD4 coreceptor-expressing indicator cells (Table 1). Infected cells were detected by immunostaining for viral antigens and counted. All data are representative of those from at least three independent experiments.
infection in comparison to an IgG1 isotype control. Taken together, these data confirm that the inhibition observed by RANTES is not due to the expression and use of CCR5 on these cells. Astrocyte infection was not affected by the CXCR4 antagonist AMD3100 or the CCR8-specific ligand I309. The same chemokines that weakly reduced infection of CD4<sup>+</sup> adult astrocytes 001A (vMIP-I, eotaxin, and RANTES) also inhibited infection in the absence of CD4 by between 50 and 60% (Fig. 4B). Intriguingly, infection of CD4<sup>+</sup> 001A cells was completely blocked by the CD4 MAb Q4120, indicating the presence of low levels of CD4 undetectable by immunostaining (Fig. 1) but sufficient to explain the observed infection by the HIV-1 strains GUN-1v and HAN-2 in the absence of adenovirus-mediated CD4 expression. As seen in Fig. 4A, CD4<sup>+</sup> astrocyte infection was also unaffected by 2D7. Infection of the fetal astrocyte preparation F01 by GUN-1v was reduced to less than 10% of control levels by AMD3100 and was minimally affected by RANTES, I309, and vMIP-I, confirming that CXCR4 conferred the majority of infection in these cells (Fig. 4C). The observation that adult astrocyte infection can be inhibited by chemokines implies a role for a chemokine receptor(s) in virus entry into these cells. However, weak inhibition was observed with several chemokines, all of which interact with a range of chemokine receptors (vMIP-I, RANTES, and eotaxin), suggesting that the chemokine receptor exploited for infection of astrocytes is not a major target for these chemokines.

**BMVEC support infection by the same viruses shown to infect astrocytes via an unidentified coreceptor.** We next tested the ability of primary BMVECs to support infection by a range of HIV-1, HIV-2, and SIV isolates. No infection by HIV-1 and HIV-2 isolates that predominantly use CCR5 or CXCR4 was observed. However, the same subset of viruses that infected adult astrocytes also replicated in BMVECs. These included R5X4 HIV-1 strains (GUN-1v and HAN-2), HIV-2 strains (TER), and SIV strains (17Efr) (Fig. 5A). In addition, the R5X4 HIV-2 isolates JAU and MLC and the SIV variant SIVmac316 infected BMVECs. BMVEC infection by GUN-1v was completely inhibited by vMIP-I (Fig. 5B) but was unaffected by ligands for CCR5 (AOP-RANTES), CXCR4 (AMD3100), and CCR8 (I309), despite their ability to block infection of coreceptor-expressing cell lines (data not shown). The CCR3 ligand eotaxin reduced BMVEC infection by approximately 30%; however, the chemokine analogue vMIP-II, a more potent inhibitor of CCR3, had no effect on infection (43, 66). BMVEC infection was reduced to less than 5% by the CD4 MAbs Q4120 (D1) and 5A8 (D2/3), indicating that CD4 was present on the cell surface at levels high enough to support
FIG. 4. Infection of CD4+ astrocytes is partially inhibited by vMIP-I and RANTES. Adult-derived astrocytes 001A either pretreated with Ad-CD4 (A) or untreated (B) and fetal astrocytes F01 (C) were preincubated with a range of chemokines or small-molecule inhibitors at 500 nM or with antibodies at 5 μg/ml before being exposed to the HIV-1 isolate GUN-1v. Infected cells were detected by immunostaining for p24 at 72 h postinfection. One hundred percent infection represents the titer in the absence of inhibitor and was approximately 150 FFU. All values were calculated with respect to this control. All samples were done in duplicate, and the error bars represent the standard errors of the means.
the efficient infection observed by the HIV and SIV strains shown in Fig. 5. The corresponding antibody isotype control, IgG1, had no effect on BMVEC infection. Infection of BMVECs therefore identifies the same subset of HIV-1, HIV-2, and SIV strains that infect GFAP⁺ astrocytes. Complete inhibition of BMVEC infection by vMIP-I, as well as the lack of inhibition by potent ligands for CCR5 and CXCR4, confirms that an alternative coreceptor is responsible for virus entry.

A subset of HIV and SIV isolates can infect Δ32/Δ32 CCR5 PBMCs with CXCR4 blocked by AMD3100. The experiments described above provide evidence that BMVECs and astrocytes naturally express alternative coreceptors that are functional for a subset of HIV-1 strains. Since these cells are not the major targets for HIV-1 in vivo, we tested whether the HIV and SIV isolates had the capacity to exploit an alternative coreceptor(s) on PBMCs. For this we used PBMCs prepared from an individual homozygous for the 32-bp deletion in CCR5 (Δ32/Δ32 CCR5) and blocked CXCR4 by treatment with AMD3100. The R5 HIV-1 isolate SF162 was unable to infect these cells, since they do not express CCR5 (data not shown). Infection of wt/wt CCR5 PBMCs by SF162 was not inhibited by the ligand AMD3100 (CXCR4) or vMIP-I (CCR8, GPR1, and CXCR6), either alone or in combination (Fig. 6A). Together these data demonstrate that SF162 infection of PBMCs is entirely CCR5 dependent. On Δ32/Δ32 CCR5 PBMCs, the X4 strain 2044 was efficiently inhibited by AMD3100 but not vMIP-I, although a slight delay in the rate of replication of this virus was noted (Fig. 6B). The HIV-1 isolate HAN-2 and

FIG. 5. BMVECs support infection by the same subset of HIV and SIV isolates that infect astrocytes. (A) Untransformed BMVECs were exposed to HIV and SIV strains, and intracellular viral antigens were detected by immunostaining following a 72-h incubation. (B) The sensitivity of BMVEC infection to chemokine inhibition was determined by preincubating cells with chemokines or small molecule inhibitors at 200 nM or with CD4 MAbs at 5 μg/ml before incubation with the HIV-1 isolate GUN-1v. Infections were performed in duplicate, and error bars represent the standard errors of the means. Results are representative of those from at least two independent experiments.
HIV-2 TER replicated in the presence of AMD3100 (Fig. 6C and E). A second HIV-1 isolate, P1019, consistently replicated in the presence of AMD3100, albeit at low levels (Fig. 6D). Replication by each of these viruses was completely inhibited when cells were pretreated with vMIP-I in addition to AMD3100, yet pretreatment with I309 in addition to AMD3100 had no effect on any of the isolates tested (data not shown). We also tested GUN-1v; however, this T-cell-line-adapted virus replicated poorly in both wt/wt and Δ32/Δ32 CCR5 PBMCs. GUN-1v replication eventually ensued after a long lag phase; however, the impact of adaptive changes occurring during this lag time on GUN-1v coreceptor use is unclear. GUN-1v data were therefore omitted from this study.

The results described above thus show that the primary HIV-1 and HIV-2 strains that infect astrocytes and BMVECs are also able to exploit an alternative coreceptor on PBMCs, a major target for HIV infection in vivo.

Analysis of HIV and SIV receptor expression on untransformed cell types. RT-PCR was carried out on mRNA extracted from the three astrocyte cultures, BMVECs, Δ32/Δ32 PBMCs, and macrophages, to determine the pattern of HIV coreceptor expression. All mRNA preparations were positive for the housekeeping GAPDH gene (Fig. 7A). CD4 was found to be strongly expressed in Δ32/Δ32 CCR5 PBMCs and macrophages, as expected, but, surprisingly, also in the adult astrocytes 004.2 (Fig. 7B). BMVECs and the adult astrocyte culture 001A were very weakly positive for CD4 (Fig. 4B and 5B, respectively). A truncated CCR5 signal was detected for Δ32/Δ32 PBMCs and macrophages but not for any of the other cell cultures tested. CXCR6 expression was detected in PBMCs only. CXCR4 mRNA was expressed in Δ32/Δ32 PBMCs and macrophages, as well as in the fetal astrocyte culture F01. Although CCR3 and CCR8 were undetectable on Δ32/Δ32 PBMCs after 25 cycles, a signal was detected after amplification for 35 cycles (Fig. 7C). All other coreceptors screened for, including CCR3, CCR8, GPR1, and GPR15, were negative on all other primary cell cultures after 25 and 35 cycles (Fig. 7C). The orphan receptor RDC1 was detected in Δ32/Δ32 PBMCs, in the fetal F01 astrocytes, and weakly in the adult 004.2 astrocytes. In contrast to other studies (64), the parental NP2/CD4 cell line was also positive for this receptor. mRNA detection for each of the coreceptors tested here therefore did not correlate with HIV or SIV infection via the alternative coreceptor. We thus conclude that an as-yet-unidentified receptor for vMIP-I is partially (astrocytes) or wholly (BMVECs and PBMCs) responsible for infection of several untransformed cell cultures.

FIG. 6. Productive infection of Δ32/Δ32 CCR5 PBMCs by HIV and SIV strains with CXCR4 blocked. Δ32/Δ32 CCR5 or wt/wt CCR5 PBMCs were preincubated for 1 h with medium alone or the inhibitor AMD3100, vMIP-I, or AMD3100 plus vMIP-I at 1,000 nM before addition of virus. (A) wt/wt CCR5 PBMCs were infected in triplicate with the R5 HIV-1 strain SF162. (B to G) Δ32/Δ32 CCR5 PBMCs were infected in triplicate with all other viruses (2044, HAN-2, P1019, TER, ETP, and SIVman4). All virus stocks had titers of between 10⁴ and 10⁵ FFU/ml on NP2/CD4/CCR5 or NP2/CD4/CXCR4 indicator cell lines. Supernatant was removed every 3 days up to day 18, and virus production was measured by RT enzyme-linked immunosorbent assay. All points represent the average for triplicate samples, and infections are representative of at least two independent infections.
DISCUSSION

A wide range of different seven-transmembrane G-protein-coupled chemokine receptors function as coreceptors for HIV infection of indicator cell lines in vitro. Many HIV-2 and SIV strains are particularly promiscuous for different coreceptors in such assays; however, HIV-1 strains can also use a variety of alternative coreceptors (16, 53), e.g., CCR3, CCR8, and
CXCR6. Although some of these coreceptors are expressed on CD4+ primary cells (1, 34, 61), there is little current evidence to suggest they are used by HIV-1 in vivo. Thus, the ability of particular HIV-1 strains to exploit alternative coreceptors for infection of cell lines in vitro does not provide a true indication of virus coreceptor use in vivo. We therefore analyzed several untransformed cell cultures for natural expression of functional alternative coreceptors that support HIV and SIV infection.

Astrocytes established from adult temporal lobe samples and untransformed BMVEC cultures do not express either CCR5 or CXCR4 and thus represent suitable target cells to test for the presence of alternative coreceptors. BMVECs and adult astrocytes expressing CD4 (via Ad-CD4) were resistant to infection by HIV and SIV strains that predominantly utilize CCR5 or CXCR4 alone. Both BMVECs and adult astrocytes were susceptible to infection by a subset of R5X4 HIV-1 strains, including two primary isolates (HAN-2 and P1019) as well as GUN-1v. GUN-1v is a variant virus isolated in vitro by its capacity to infect a wider range of host cells, including BT cells (human CD4+ meningo-derived cells) (65, 71). GUN-1v infection of BMVECs was sensitive to inhibition by vMIP-I (an HHV8-encoded chemokine), suggesting that a receptor for this ligand is important for infection of these cells. In contrast, astrocyte infection by GUN-1v was reduced only approximately 50% by vMIP-I. This lack of complete inhibition by vMIP-I suggests either that the vMIP-I receptor (implicated for infection of BMVECs) is not solely responsible for astrocyte infection or that vMIP-I only weakly inhibits this receptor as expressed on astrocytes.

Infection of astrocytes was also reduced approximately 50% by the chemokines RANTES and eotaxin. These ligands each bind several chemokine receptors (CCR1, CCR3, CCR5, and CCR9 for RANTES and CCR3 and D6 for eotaxin), indicating a role for this subclass of receptor in the infection of astrocytes. Although CCR5 expression was not detected on these astrocytes, several groups have reported expression on astrocytes in situ in the brain, which is lost rapidly in culture (8, 29, 44). The lack of inhibition by the CCR5 small-molecule inhibitor TAK-779, as well as by the CCR5-specific MAb 2D7, confirms that the weak inhibition by RANTES was not due to the presence of low levels of CCR5.

There is evidence that astrocytes become persistently infected by HIV-1 in vivo, particularly in pediatric AIDS (57, 70, 74). Since R5 viruses are predominant in the brain (1, 37, 62), it is possible that these astrocytes are infected in vivo via CCR5. Nevertheless, the alternative coreceptor demonstrated on these CCR5+ cultured astrocytes may potentially confer infection of astrocyte subsets critical for brain homeostasis and thus have an impact on neuropathology. In this study we used MAbs that detect p24 as a marker for HIV-1 infection. Since p24 is a late gene product, our results show that the astrocyte infection observed here in vitro is not restricted to the early phase of viral replication and expression of early gene products, thus confirming the observations of Canki et al. (10).

Since BMVECs and astrocytes are not major targets for HIV-1 in vivo, we sought evidence for use of the alternative coreceptor on primary PBMCs. Other studies have demonstrated the ability of some SIV strains to infect PBMCs lacking CCR5 via an alternative coreceptor, in a donor-dependent manner (11, 78). In some instances CXCR6 was implicated as the coreceptor involved (79, 80). In confirmation, several HIV-1 and HIV-2 isolates identified here that exploit an alternative coreceptor(s) for BMVEC and astrocyte infection were able to replicate in PBMCs that lack CCR5, with CXCR4 blocked by AMD3100. The X4 isolate 2044 was consistently sensitive to inhibition by AMD3100, although low-level residual replication was sometimes detected even in the presence of AMD3100. However, AMD3100-resistant replication in PBMCs by the isolates HAN-2, P1019, TER, and Man4 was not due to residual use of CXCR4, since such replication was inhibited by vMIP-I, a chemokine that does not interact with CXCR4 (20, 67). Our observations therefore provide evidence that an alternative coreceptor is active for infection of PBMCs by the HIV and SIV strains described.

The identity of the alternative coreceptor remains to be conclusively elucidated. A hallmark of the BMVEC and PBMC infection via an alternative coreceptor demonstrated here was the sensitivity to inhibition by vMIP-I. To date, vMIP-I has been reported to inhibit HIV infection mediated through CCR8 (20, 33) as well as GPR1 and CXCR6 (66). GUN-1v and the other HIV and SIV strains, identified here by their capacity to use alternative coreceptors, were able to use CCR8 and GPR1 (as well as other coreceptors) in addition to CCR5 and CXCR4 as coreceptors on cell lines. Furthermore, GUN-1v has previously been reported to use alternative coreceptors for infection of astroglial U87 cells, primary mesangial kidney cells, and BT cells. CCR8 was implicated as a coreceptor for BT infection (40) and GPR1 was implicated as a coreceptor for mesengial cell infection (73); however, inhibition by ligands to these coreceptors was not demonstrated. Our observations that the CCR8 ligand I309 had no effect on the replication of any HIV or SIV isolate in BMVECs or Δ32/Δ32 PBMCs, alone or in combination with AMD3100, despite being able to inhibit infection of a CCR8-expressing indicator cell line (data not shown) implies that vMIP-I is able to inhibit HIV infection of PBMCs via another chemokine receptor.

We also attempted to correlate coreceptor mRNA detection in PBMCs, BMVECs, and astrocytes with infection by this subset of HIV and SIV strains. None of the presently known vMIP-I receptors (CCR8, GPR1, and CXCR6) were detected by RT-PCR in BMVECs. mRNA for CCR8 was detected in the Δ32/Δ32 PBMCs; however, the CCR8-specific chemokine I309 had no effect on viral replication in either PBMCs or BMVECs. Δ32/Δ32 CCR5 PBMCs were also positive for expression of CXCR6, a coreceptor previously implicated as being responsible for replication of a maternal HIV-1 isolate (61, 79, 80). However, the CXCR6 ligand CXCL16 failed to block replication of vMIP-I-sensitive virus strains on Δ32/Δ32 CCR5 PBMCs even though infection of CXCR6-expressing cell lines was efficiently inhibited (data not shown). Finally, mRNA for GPR1 was not detected in either BMVECs or PBMCs. We therefore believe that an as-yet-unidentified vMIP-I receptor is responsible for the HIV and SIV infection of these cells. An alternative, albeit less likely, explanation is that vMIP-I induces down-modulation of a different receptor or induces intracellular signaling responses that negatively affect viral replication. However, previous studies have demonstrated that vMIP-I has no effect on chemokine-induced intracellular calcium signaling via the chemokine receptors CCR2, CCR4, CCR5, CCR7,
CXCR2, CXCR3, and CXCR4 on PBMCs (20). Although vMIP-I did desensitize CCR8-mediated signaling, its ineffec-
tiveness against such a large range of chemokine receptors suggests that receptor desensitization is not the mechanism of inhibition observed here.

All viruses that we found to use an alternative coreceptor(s) are R5X4, with the exception of HIV-2 T ER, an isolate that readily acquires CXCR4 use in culture. We believe that an alternative coreceptor(s) may be exploited late in disease in readily acquires CXCR4 use in culture. We believe that an alternative coreceptor(s) may be exploited late in disease in readily acquires CXCR4 use in culture. We believe that an alternative coreceptor(s) may be exploited late in disease in readily acquires CXCR4 use in culture. We believe that an alternative coreceptor(s) may be exploited late in disease in readily acquires CXCR4 use in culture. We believe that an alternative coreceptor(s) may be exploited late in disease in readily acquires CXCR4 use in culture. We believe that an alternative coreceptor(s) may be exploited late in disease in readily acquires CXCR4 use in culture. We believe that an alternative coreceptor(s) may be exploited late in disease in readily acquires CXCR4 use in culture. We believe that an alternative coreceptor(s) may be exploited late in disease in readily acquires CXCR4 use in culture. We believe that an alternative coreceptor(s) may be exploited late in disease in readily acquires CXCR4 use in culture. We believe that an alternative coreceptor(s) may be exploited late in disease in readily acquires CXCR4 use in culture.

ACKNOWLEDGMENTS

This work was supported by grants from amFAR (02802-30-RG) and the NIH (MH64408-01). S.J.W. is supported by Pfizer Global Research and Development, United Kingdom. A.M. is a recipient of a Wellcome Trust Fellowship, United Kingdom. P.R.C is an Elizabeth Glaser Research Scientist.

We are grateful for the support, encouragement, and excellent discussion from Patrick Dorr and Manos Poros at Pfizer Global Research and Development, Ltd. Hiroo Hoshino very generously provided the HIV-1 strain GUN-IV and coreceptor-expressing NP2 cells. We thank Brad Poulos at the Albert Einstein Human Tissue Repository for fetal brain samples for astrocyte culture. We are grateful to the EU Programme EVA/MRC Centralised Facility for AIDS Reagents, NIBSC, United Kingdom (grant no. QLK2-CT-1999-00609 and GPS28102), and the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, for reagents used in this study.

REFERENCES


575
601
is a specific agonist for the CC chemokine receptor (CCR5) [J. Exp. Med. 189:1993–1998].


